Skyhawk Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial

Skyhawk Therapeutics to Present Preclinical Data of SKY-1214 Combination Treatment in Hematologic Cancers at the 66th American Society of Hematology Annual Meeting

Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Skyhawk Therapeutics to Present Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Skyhawk Therapeutics to Present Additional Positive Topline Data from Parts A and B of Phase 1 Clinical Trial of SKY-0515 at European Huntington's Disease Network and Enroll-HD 2024

Skyhawk Therapeutics Announces Positive Topline Results of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction

Skyhawk Therapeutics Expands into State-of-the-Art Labs in its Basel, Switzerland Location

Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Haney to Executive Chairman

Ipsen, Skyhawk ink deal worth up to $1.8B

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D

Skyhawk Has Advanced to Multiple Ascending Dose in it’s SKY-0515 Huntington’s Trial

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small

Drugging RNA

Drugging RNA with Pills : Small Molecules for a Big Frontier

Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

Bill Haney’s latest startup scores deal from Sanofi its newest Big Pharma partner, with $54M upfront

Skyhawk Therapeutics Completes New Investment Round

Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic

Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President